New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent
Ascelia Pharma AB (publ) (ticker: ACE) today announced the results from an independent reader study where Mangoral was compared against a gadolinium-based liver specific contrast agent. The results showed that Mangoral was as effective as the gadolinium-based contrast agent gadobenate dimeglumine for visualization of focal liver lesions. The results also showed that Mangoral-enhanced MRI provides improved diagnostic efficacy compared to MRI without a contrast agent using identical endpoints as in Ascelia Pharma’s ongoing pivotal Phase 3 study SPARKLE.The blinded re-read study was performed